Tick-borne parasitic infection

Babesia

Red blood cell parasite causing cyclical fevers, sweats, chills, air hunger, and anemia. Found in 65–80% of chronic Lyme patients. Species awareness and anti-parasitic treatment sequencing are essential.

Causes and drivers

Babesia is a red-blood-cell parasite, not just another Lyme symptom.

Babesia species infect red blood cells and can spread by tick bite, transfusion, and rarely from mother to baby. Illness can be mild, relapsing, or severe, especially without a spleen, with immune suppression, in pregnancy, in older adults, or when co-infections and mold/CIRS are present. Horowitz's Babesia series emphasizes B. microti, B. duncani, B. divergens-like strains, and emerging B. odocoilei in resistant presentations. Henry Lindner, MD's 2022 Pennsylvania Senate presentation adds a sequestering-Babesia framework for B. odocoilei: deer/tick ecology, capillary "nest" behavior, and the possibility that venous smears can miss organisms when the clinical pattern remains highly suggestive.

Common patient clues

Document sweats, chills, fever waves, air hunger, chest pressure, profound fatigue, dark urine, headaches, dizziness, anxiety surges, and symptoms that flare in cycles.

Laboratory evidence

Blood smear, PCR, antibody testing, FISH, CBC, liver enzymes, bilirubin, LDH, haptoglobin, reticulocytes, kidney markers, and platelet trends help clinicians assess severity and timing.

Urgent risk factors

Seek urgent medical care for severe shortness of breath, fainting, confusion, chest pain, jaundice, dark urine with weakness, high fever, pregnancy, immune suppression, or no spleen.

Clinician-supervised treatment protocols

Horowitz Babesia protocols: from standard CDC regimens to tafenoquine-based combination therapy for resistant cases.

Dr. Richard Horowitz has been treating and publishing on Babesia since the late 1990s. His 3-part October 2024 Medical Detective Substack series documents a 25-year evolution from Clindamycin/Quinine through Mepron/Zithromax, mefloquine, Coartem, dapsone, and ultimately tafenoquine-based combination therapy. Babesia persists in 65–80%+ of his chronic Lyme/PTLDS patients. Anti-parasitic medications require specialist monitoring for QT interval, hemolysis, methemoglobin, and psychiatric safety.

Horowitz 2024 — latest published protocol

Tafenoquine + Atovaquone Combination Therapy for Resistant Babesia

Published in Horowitz's October 30, 2024 Medical Detective Substack (Babesia Part 3 of 3). This is the most recent advancement for patients who have failed standard Mepron/Zithromax, Clindamycin/Quinine, Coartem, or dapsone-based protocols. Tafenoquine is an FDA-approved anti-malarial used off-label for resistant Babesiosis. B. microti and B. duncani have demonstrated genetic resistance to standard therapies, and B. duncani has an unusually high tolerance to recommended treatments.

Horowitz Tafenoquine + Atovaquone Protocol (exact from Oct 30, 2024 Substack)

Phase Medication Dose & Schedule
Loading dose
(first 3 days)		 Tafenoquine (Arakoda, Rx) 100 mg tablets: 2 tablets once daily = 200 mg/day for 3 consecutive days = 600 mg total loading dose
Atovaquone (Mepron, Rx) 750 mg (5 mL) twice daily. For B. microti, Horowitz uses 1500 mg twice daily as lower doses do not clear B. microti as well
Maintenance
(6 weeks)		 Tafenoquine (weekly) 200 mg once weekly (2 x 100 mg tablets). For improved B. microti clearance, Horowitz often uses 300 mg once weekly (3 tablets). Continue for 6 weeks total
Atovaquone (daily) 750–1500 mg twice daily. Continue for 6 weeks alongside weekly tafenoquine
Adjunctive agents
(added for resistance)		 Azithromycin (Zithromax, Rx) 250–500 mg twice daily. Macrolide with anti-Babesia activity, used alongside tafenoquine + atovaquone
Ivermectin (Rx) 0.2 mg/kg once daily. Anti-parasitic; Horowitz adds this for complex/resistant cases

Methemoglobin management during tafenoquine therapy

Supplement Dose Purpose
Glutathione (liposomal)At least 1000 mg twice dailyPrimary antioxidant to reverse methemoglobin
Vitamin C1 gram twice dailyAntioxidant methemoglobin support
Vitamin E300 IU twice dailyRed blood cell membrane protection
Cimetidine (Rx)400 mg twice dailyCYP450 inhibitor; helps manage methemoglobin and Herxheimer reactions
Methylene blueAt least 100 mg twice dailyDirect methemoglobin reversal agent; also has anti-malarial and anti-Babesia activity

Critical safety warning — from Horowitz's Substack: Tafenoquine and dapsone should NOT generally be given at the same time due to additive methemoglobin risk. G6PD must be normal before starting. Tafenoquine carries psychiatric risk (suicidality, psychosis) similar to its cousin mefloquine, and can cause hemolytic anemia and elevated methemoglobin. Contraindicated in pregnancy. Full side effect profile in the PDR should be consulted. Methemoglobin levels must be monitored during treatment.

* Tafenoquine for Babesia is off-label. Tafenoquine (Arakoda) is FDA-approved for malaria prophylaxis only. Its use in Babesiosis is clinician-directed, off-label, and requires G6PD testing, methemoglobin monitoring, psychiatric screening, and pregnancy review. Do not self-prescribe. *

Detailed clinical picture

Babesia deserves its own workup because it infects red blood cells.

Babesiosis can be silent, mild, relapsing, or life-threatening. A good history captures fever cycles, oxygen-like symptoms, anemia clues, risk factors, and geography.

Symptoms that point toward Babesia

  • Cycles: fever waves, chills, night sweats, drenching sweats, temperature swings, and flares that return every few days or weeks.
  • Oxygen-like symptoms: air hunger, sighing, shortness of breath without clear lung disease, chest pressure, exercise intolerance, and feeling unable to get a full breath.
  • Blood-cell clues: anemia, low platelets, elevated bilirubin, elevated liver enzymes, dark urine, jaundice, enlarged spleen or liver, and profound weakness.
  • Nervous-system overlap: headaches, dizziness, anxiety surges, sleep disruption, brain fog, neuropathic pain, and worsening of underlying Lyme symptoms.

Higher-risk situations

  • No spleen, impaired spleen function, cancer therapy, transplant medications, immune suppression, HIV, older age, pregnancy, newborn exposure, or severe chronic illness.
  • Known blood transfusion exposure or blood donation after suspected babesiosis. Patients should discuss donation safety with a clinician and blood bank guidance.
  • Geography or travel to areas where Babesia microti, Babesia duncani, or other Babesia-like organisms are reported.
  • Symptoms after a tick bite plus lab patterns suggesting hemolysis, low platelets, or liver stress.

Babesia species clinicians should account for

Species or strain Why it matters Testing and care focus
Babesia microti Most commonly identified U.S. human Babesia species, especially in the Northeast and upper Midwest. It can relapse or persist in immunocompromised patients and can be transfusion-associated. CDC-listed treatment categories, smear/PCR/serology, hemolysis labs, immune-status review, and resistant-case discussion when symptoms or testing persist.
Babesia duncani / WA-1 Reported on the West Coast and discussed by Horowitz as a more treatment-tolerant or resistant Babesia species. Standard B. microti-only serology can miss it. Species-aware testing, FISH/PCR/antibody strategy, air-hunger and sweat tracking, and specialist treatment planning when relapse patterns continue.
Babesia odocoilei White-tailed-deer-associated Babesia discussed by Horowitz, Lindner, and other specialty clinicians in highly resistant chronic presentations. Lindner cites deer-tick ecology, Ontario tick findings, and veterinary literature suggesting possible capillary/venule sequestration in "nests," which may help explain negative venous smears in some suspected cases. LADA flags it as a high-resistance concern while noting that mainstream literature continues to debate human pathogenicity and testing interpretation. Document deer-tick exposure, geography, cyclic air hunger/sweats, hemolysis clues, and any B. duncani antibody pattern in eastern or Canadian settings. Discuss specialty FISH/broad Babesia testing, capillary smear consideration, and clinician-supervised resistant-case strategies such as tafenoquine-based combinations only when the full risk profile supports it.
Babesia divergens A European species that can be severe, especially in patients without a spleen. CDC notes B. divergens infections tend to be more severe than typical B. microti. Urgent evaluation for severe hemolysis, travel/residence history, smear/PCR support, hospital-level care when parasitemia or organ involvement is serious.
MO-1 A B. divergens-like strain reported in Missouri. It belongs in the rare Babesia differential when severe illness, geography, and lab findings fit. Public health or specialty molecular testing, smear review, hemolysis labs, and urgent care planning in high-risk patients.
KO-1 A rare B. divergens-like organism reported in Asia. It is mainly relevant for travel, immigration, military, field-work, or animal-exposure histories. Travel-aware testing, infectious-disease consultation, public health lab support, and malaria/Babesia distinction on smear and molecular testing.
Babesia venatorum / EU-1 Reported in Europe and Asia, with higher concern in immunocompromised patients. It may not be covered by routine U.S. panels. Travel and immune-status history, species-aware PCR or reference-lab testing, and close monitoring for anemia or organ stress.
Babesia bovis Primarily a cattle Babesia, but it appears in Horowitz's global species list and belongs in a livestock/travel-aware differential when exposure is unusual. Veterinary or zoonotic exposure history, public health or reference-lab input, and avoidance of assumptions based on a standard B. microti panel alone.
Babesia bigemina Another major cattle Babesia in global veterinary medicine. Human relevance is uncommon, but it matters when livestock, travel, and severe hemolysis clues line up. Travel/livestock exposure documentation, smear morphology support, and molecular confirmation through specialized channels.
Babesia major A ruminant-associated Babesia noted in broad species discussions. It is rare in human care but should not be ignored when exposure history is unusual. Specialist differential diagnosis, reference-lab consultation, and parallel evaluation for more common causes of fever and hemolysis.
Babesia crassa A sheep/goat-associated Babesia in global piroplasm discussions. Human testing is not routine, so geography and animal exposure carry extra weight. Travel and livestock history, public health guidance, and clinician review of whether testing is clinically meaningful.
Babesia occultans A cattle-associated Babesia included in Horowitz's list of species to keep in mind. It is mainly a rare/global exposure consideration. Specialty consultation when severe Babesia-like illness follows relevant travel or animal exposure and common panels are unrevealing.

Lindner 2022: B. odocoilei and the sequestering Babesia framework

Lindner focus What the presentation adds How patients can use it with a clinician
Deer-tick ecology Lindner highlights B. odocoilei as a white-tailed-deer Babesia and cites tick studies from Pennsylvania and southern Ontario, including reports of B. odocoilei in Ixodes scapularis ticks. Bring a location and exposure timeline: tick bites, deer-heavy property, hunting/field work, pets, travel, and whether standard B. microti testing matched the symptom pattern.
Possible antibody cross-reaction The presentation raises the possibility that some B. duncani antibody results in eastern North America may reflect cross-reactivity with B. odocoilei, rather than true West Coast B. duncani. Do not treat a single antibody result as a complete species answer. Ask whether additional Babesia FISH, immunoblot, PCR, smear timing, or reference-lab input would change care.
Capillary/venule sequestration Using veterinary Babesia literature, Lindner describes infected red blood cells lodging in small vessels and forming capillary or venule "nests," where organisms may be sparse in ordinary venous blood. If symptoms persist but venous smear/PCR is negative, discuss whether capillary blood smear or specialty FISH is reasonable, especially during fever, sweat, air-hunger, or exertional-crash flares.
Testing limitations Lindner emphasizes that B. odocoilei has no routine antibody test, venous smears may be negative, and IGeneX FISH/immunoblot or TLab FISH can still be false-negative. Track symptoms and labs over time instead of relying on one negative test. CBC, platelets, bilirubin, LDH, haptoglobin, reticulocytes, liver enzymes, and kidney markers can help show risk and timing.
Neuro-exertional pattern Lindner's presentation connects suspected sequestering Babesia with exertional intolerance and encephalopathy-like symptoms, while also stressing overlap with Bartonella and other tick-borne infections. Bring objective notes: post-exertional crashes, cognitive changes, dizziness, psychiatric worsening, sleep disruption, and co-infection history. Seek urgent help for confusion, severe shortness of breath, chest pain, suicidality, or fainting.
Treatment implications Lindner argues that sequestered Babesia may require prolonged, multi-agent, specialist-supervised care and discusses fibrin or nest disruption as a specialist concept. This is not a self-treatment protocol. Use this as a reason to find an experienced clinician, not to self-prescribe. Anti-Babesia drugs and adjuncts can involve G6PD risk, hemolysis, QT effects, methemoglobin, psychiatric warnings, pregnancy issues, and drug interactions.

Babesia workup and treatment guide

Clinical issue Why it matters Clinician evaluation focus
Species and geography Different species and Babesia-like organisms may require different test panels, and routine labs may not cover all clinically relevant possibilities. Species fit by location, travel, tick exposure, immune status, and available test methods.
Direct testing Blood smear, PCR, and FISH can miss low-level, intermittent, or possibly sequestered infection, but positives can be very useful when timing is right. Repeat testing during fever or sweat flares, combine direct and antibody methods when appropriate, and discuss capillary blood smear or specialty FISH when B. odocoilei or another sequestering species is suspected.
Routine labs CBC, platelets, bilirubin, LDH, haptoglobin, reticulocytes, kidney markers, and liver enzymes can show severity and hemolysis risk. Evidence of red-cell destruction, liver stress, low platelets, kidney stress, or severe parasitemia.
Treatment safety Anti-parasitic medications can interact with other drugs and may require monitoring for liver, cardiac, blood-count, pregnancy, and tolerance issues. Baseline labs, interaction checks, pregnancy considerations, and urgent stop rules before treatment.

Recommended Babesia tests to discuss

Testing category Horowitz / Kinderlehrer / Lindner focus Common tests and labs to discuss
Acute or severe Babesia workup Horowitz and conventional guidance both treat high-risk Babesia as a red-blood-cell infection that can become urgent, especially in asplenia, pregnancy, older age, or immune suppression. Thin blood smear with parasitemia estimate, Babesia PCR, CBC with platelets, CMP, bilirubin, LDH, haptoglobin, reticulocyte count, urinalysis for hemoglobin/dark urine, kidney markers, and hospital-level evaluation when severe.
Species-aware testing Horowitz and Kinderlehrer emphasize that B. microti-only testing can miss clinically important Babesia-like illness. B. microti IgG/IgM, PCR, and smear; B. duncani/WA-1 IFA or immunoblot when geography or resistant symptoms fit; B. divergens-like and MO-1/KO-1 reference-lab testing when travel, severity, or splenic risk fits.
FISH and low-level infection Horowitz's FISH research supports direct detection when serology is negative or immune response is unreliable, while acknowledging that timing and parasite load matter. Babesia FISH through specialty labs, PCR during fever/sweat/air-hunger flares, repeat direct testing when early or single samples were negative, and combined antibody plus direct testing when clinically justified.
B. odocoilei / sequestering Babesia Lindner's work adds a capillary-blood and sequestration framework for suspected B. odocoilei; Horowitz flags this species in resistant Babesia discussions. No routine antibody test is established. Discuss TLab for B. odocoilei-focused Babesia testing, TLab/IGeneX-style FISH, specialty Babesia panels, capillary blood smear or capillary sampling when a clinician is experienced with it, and careful interpretation of B. duncani antibody results in eastern/Canadian settings.
Co-infections and immune status Kinderlehrer and Horowitz both frame Babesia in the larger Lyme-MSIDS picture: Babesia may coexist with Lyme, Bartonella, Anaplasma/Ehrlichia, mold/CIRS, MCAS, and immune suppression. Lyme/Borrelia testing, Bartonella serology/PCR/FISH/enrichment culture, Anaplasma/Ehrlichia PCR or paired serology, immunoglobulins when immune suppression is suspected, spleen history, medication list, and transfusion/pregnancy history.
Tafenoquine / dapsone safety labs Horowitz's tafenoquine-based and dapsone-adjacent protocols require careful safety screening because these drugs can affect red blood cells, methemoglobin, QT risk, mood, and pregnancy safety. G6PD before tafenoquine or dapsone, CBC with differential, CMP, bilirubin, methemoglobin, reticulocytes, ECG/QT review, psychiatric screening for tafenoquine/mefloquine risk, pregnancy test when relevant, and full interaction review.

* Babesia testing is timing- and species-sensitive. Severe symptoms or high-risk status should be handled urgently; specialty testing should be ordered and interpreted by a clinician. *

Educational images

Babesia: blood smear microscopy, tetrad forms, B. odocoilei, and capillary-nest visuals.

Microscopy images from CDC DPDx and Wikimedia Commons are paired with selected Henry Lindner, MD presentation slides on B. odocoilei, sequestration, and capillary-nest microscopy.

Babesia microti in red blood cells - annotated thin blood smear showing ring forms and tetrad

Babesia microti in red blood cells (Giemsa stain, annotated)

Annotated thin blood smear showing Babesia parasites inside erythrocytes. Ring forms, paired merozoites, and a tetrad (Maltese cross) are visible. The parasites appear as dark-staining bodies within the pale red blood cells. Babesia is a protozoan, more closely related to malaria (Plasmodium) than to bacteria. Source: CDC DPDx / Wikimedia Commons, public domain.

Babesia microti CDC microscopy - thin blood smear showing intraerythrocytic parasites

Babesia microti — CDC blood smear

Thin blood smear showing Babesia parasites within red blood cells. Note the characteristic pleomorphic (variable shape) forms. Unlike malaria (Plasmodium), Babesia does not produce hemozoin pigment and can form tetrads (Maltese cross). Source: CDC Public Health Image Library, public domain.

Ixodes scapularis - blacklegged tick, vector for Babesia microti

Ixodes scapularis — tick vector

The same blacklegged tick that transmits Lyme disease also transmits Babesia microti. Co-transmission is common: Horowitz finds Babesia in 65–80% of his chronic Lyme patients. Babesia can also be transmitted by blood transfusion, organ transplant, and maternal-fetal transmission.

Lindner presentation slide summarizing Babesia odocoilei and other organisms reported in deer ticks in Pennsylvania and Ontario

Lindner: B. odocoilei in deer-tick ecology

Lindner's 2022 Pennsylvania Senate presentation summarizes deer-tick data and argues that B. odocoilei belongs in the resistant Babesia differential, especially when geography, deer exposure, cyclic symptoms, and species-limited testing do not fit neatly. Source: Henry Lindner, MD, PA Senate HHS Hearing presentation, Sept. 20, 2022.

Lindner presentation slide on Babesia odocoilei veterinary literature, white-tailed deer host, sequestration, fibrin adherence, and negative venous blood smears

Lindner: sequestering B. odocoilei model

This slide links B. odocoilei to white-tailed deer and veterinary Babesia literature describing infected red blood cells lodging in small vessels. The clinical takeaway is testing caution: a negative venous smear may not settle the question in a highly suggestive case. Source: Henry Lindner, MD, PA Senate HHS Hearing presentation, Sept. 20, 2022.

Lindner presentation slide showing low-magnification Babesia capillary and venule nest fragments

Lindner: capillary and venule nest fragments

Lindner uses capillary blood microscopy to illustrate suspected Babesia nest material in patients with fatigue and exertional intolerance. LADA presents this as specialist educational material: patients should use it to ask about appropriate testing, not as proof of diagnosis from symptoms alone. Source: Henry Lindner, MD, PA Senate HHS Hearing presentation, Sept. 20, 2022.

Lindner presentation slide showing high-magnification Babesia persister forms in a suspected nest fragment

Lindner: suspected Babesia persisters in nest material

At higher magnification, Lindner's slide labels suspected persister forms and degenerating fragments within nest material. This supports the page's emphasis on specialist interpretation, repeat testing during flares, and careful differential diagnosis with Bartonella, Lyme, mold/CIRS, anemia, cardiopulmonary disease, and other causes. Source: Henry Lindner, MD, PA Senate HHS Hearing presentation, Sept. 20, 2022.

High-resolution Borrelia burgdorferi microscopy image — illustration of advanced diagnostic imaging

Babesia FISH — fluorescent in situ hybridization

IGeneX FISH test uses a fluorescent RNA probe binding to Babesia ribosomal RNA. Parasites fluoresce bright green, detectable even at low parasitemia. Covers 100+ Babesia species including B. microti, B. duncani, B. divergens, B. bovis, B. bigemina, and emerging species. More sensitive than Giemsa stain for chronic, low-level infection. See Shah, Horowitz et al. (2020) — open access with FISH images.

Research and clinical sources

Babesia care depends on severity, immune status, species, co-infections, and monitored anti-parasitic treatment.

These sources support clinician conversations about standard treatment, resistant cases, urgent care thresholds, and specialty evaluation.

Babesia red flags

Seek urgent medical care for severe shortness of breath, confusion, fainting, chest pain, jaundice, dark urine with weakness, high fever, severe dehydration, pregnancy, immune suppression, or no spleen.

  • Tell urgent-care staff if Babesia is possible.
  • Clinicians should assess whether anemia, hemolysis, low platelets, kidney stress, or liver stress needs immediate evaluation.

Sources used on this page

  • Lindner, H.H., MD (2022, Sept. 20). Chronic Bartonellosis and Babesiosis: It's Not Just About Lyme Anymore. Pennsylvania Senate Health and Human Services Hearing on SB 1188. Source for the page's B. odocoilei, capillary-blood, sequestration, and nest-fragment discussion.
  • Scott, J.D. et al. (2021). Detection of Babesia odocoilei in humans with babesiosis symptoms. Diagnostics, 11(6):947. PMID: 34070625.
  • Milnes, E.L. et al. (2019). Babesia odocoilei and zoonotic pathogens identified from Ixodes scapularis ticks in southern Ontario, Canada. Ticks and Tick-borne Diseases, 10(3):670–676. PMID: 30833200.
  • Livengood, J. et al. (2020). Detection of Babesia, Borrelia, Anaplasma, and Rickettsia spp. in adult black-legged ticks from Pennsylvania. Vector-Borne and Zoonotic Diseases, 20(6):406–411. PMID: 31976829.
  • Chauvin, A. et al. (2009). Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission. Veterinary Research, 40(2):37. PMID: 19379662.
  • Thomford, J.W. et al. (1993). Isolation and in vitro cultivation of Babesia parasites from free-ranging desert bighorn sheep and mule deer in California. Journal of Parasitology, 79(1):77–84. PMID: 8437062.
  • Bock, R. et al. (2004). Babesiosis of cattle. Parasitology, 129 Suppl:S247–S269. PMID: 15938514.
  • Schetters, T. (2019). Mechanisms involved in the persistence of Babesia canis infection in dogs. Pathogens, 8(3):94. PMID: 31261942.
  • Abraham, A. et al. (2018). Establishment of a continuous in vitro culture of Babesia duncani in human erythrocytes reveals unusually high tolerance to recommended therapies. Journal of Biological Chemistry, 293(52):19974–19981. PMID: 30463941.
  • Horowitz, R.I. (1998). Atovaquone and Azithromycin Therapy: A New Treatment Protocol for Babesiosis in Co-Infected Lyme Patients. 11th International Conference on Lyme Disease and Other Spirochetal and Tick-Borne Disorders. First published abstract on Mepron/Zithromax for Babesia, two years before the 2000 NEJM paper.
  • Horowitz, R.I. (1999). Babesiosis in Upstate New York: PCR and RNA Evidence of Co-Infection with Babesia Microti Among Ixodidae Ticks in Dutchess County, NY. 12th International Conference on Lyme Disease. Discovery of Babesia in Hudson Valley ticks and patients.
  • Horowitz, R.I. (1999). Persistent Positive Babesia PCR Despite Standard Treatment. 12th International Conference on Lyme Disease. Demonstrated Babesia persistence despite Clindamycin/Quinine and Mepron/Zithromax.
  • Horowitz, R.I. (2000). Mefloquine and Artemesia: A Prospective Trial of Combination Therapy in Chronic Babesiosis. 13th International Conference on Lyme Disease. 21.5% symptom improvement with Lariam + artemesia + doxycycline.
  • Horowitz, R.I. and Freeman, P. (2016). Dapsone combination therapy for chronic Lyme disease. J Clin Exp Dermatol Res, 7:3. First published study showing dapsone's effect on Babesia malarial-like symptoms.
  • Horowitz, R.I. and Freeman, P. (2019). Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/PTLDS. Int J Gen Med, 12:101–119. Confirmed Babesia presence in 65% of chronic Lyme patients; 80%+ B. duncani prevalence.
  • Horowitz, R.I., Shah, J. et al. (2020). Clinical usefulness of Babesia FISH testing. PMC. Demonstrated FISH test superiority over antibody-only testing in immunosuppressed patients for detecting multiple Babesia species.
  • Horowitz, R.I. (2024, Oct 16). Babesia — Don't Overlook This Persistent Parasite: Part 1. Medical Detective Substack. Epidemiology, symptoms, testing strategies, differential diagnosis of sweats/chills, B. microti vs B. duncani prevalence data.
  • Horowitz, R.I. (2024, Oct 23). Babesia — More Detailed Testing and Treatment Options in Special Populations: Part 2. Medical Detective Substack. Tick co-transmission, FISH testing, Immunoblot, pregnancy protocol (Clindamycin + Mepron + Zithromax), cardiac/neurologic complications.
  • Horowitz, R.I. (2024, Oct 30). Babesia — A Long and Tortuous Medical Journey to Find Treatment Options in a Highly Resistant Patient: Part 3. Medical Detective Substack. Tafenoquine + atovaquone protocol (600 mg loading dose, 200–300 mg weekly maintenance for 6 weeks), 5-herb protocol, methemoglobin management, drug interactions.
  • CDC: Clinical Care of Babesiosis
  • CDC DPDx: Babesiosis species and laboratory diagnosis
  • FDA label: ARAKODA (tafenoquine)
  • Shah, Horowitz et al. Babesia FISH test clinical usefulness, 2020
  • Horowitz, Freeman. Clindamycin + Mepron + Zithromax pregnancy protocol, Archives of Medical Case Reports, 2019
  • Schweig, S. et al. Johns Hopkins botanical medicines for B. duncani research
  • Daniel A. Kinderlehrer, MD, Recovery From Lyme Disease
  • McFadzean and Burrascano, The Beginner's Guide to Lyme Disease
Safety first

Babesia can require urgent care in high-risk patients.

LADA's role is to help patients recognize when Babesia belongs in the conversation and to connect them with appropriate medical support.

Find LLMD Support Take Questionnaire